Published in Mol Ther on July 03, 2012
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol Ther Oncolytics (2015) 0.95
Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet J Rare Dis (2013) 0.93
Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther (2013) 0.90
The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control. Mol Ther (2014) 0.85
Exploiting tumor epigenetics to improve oncolytic virotherapy. Front Genet (2013) 0.84
Enhancement of T cell recruitment and infiltration into tumours. Clin Exp Immunol (2014) 0.83
Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. Blood Cancer J (2013) 0.82
Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol Ther (2014) 0.82
Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat Commun (2015) 0.82
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines (2017) 0.79
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines (2017) 0.79
Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. Biomedicines (2016) 0.78
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
Using targeted virotherapy to treat a resistant Ewing sarcoma model: from the bedside to the bench and back. ScientificWorldJournal (2014) 0.76
Viruses as nanomedicine for cancer. Int J Nanomedicine (2016) 0.76
Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother (2013) 0.75
Emerging role of Natural killer cells in oncolytic virotherapy. Immunotargets Ther (2015) 0.75
Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. Mol Ther Oncolytics (2016) 0.75
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic Virother (2015) 0.75
Interleukin-4 Expressed By Neoplastic Cells Provokes an Anti-Metastatic Myeloid Immune Response. J Clin Cell Immunol (2015) 0.75
Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. PLoS One (2017) 0.75
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med (2011) 3.60
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol (1999) 3.04
Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res (2003) 3.04
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther (2008) 2.72
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 2.65
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 2.14
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
How tumours escape mass destruction. Oncogene (2008) 1.82
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer (1999) 1.33
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res (2008) 1.33
Detection of intracellular cytokines by flow cytometry. Curr Protoc Immunol (2007) 1.32
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther (2008) 1.16
Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther (2010) 1.13
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2010) 1.12
Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother (2011) 1.04
A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother (1992) 0.98
Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res (1983) 0.95
Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother (2011) 0.91
In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur J Cancer (1991) 0.90
CD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recovery. Cytotherapy (2007) 0.89
Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice. Cancer Immunol Immunother (1998) 0.85
Melanoma immunotherapy. Mt Sinai J Med (2010) 0.81
Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer (1985) 0.81
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer (1986) 0.80
Expression of CD69 on T-cell subsets in HIV-1 disease. Scand J Clin Lab Invest (2008) 0.77
An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell (2003) 15.12
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Endothelial cell migration during angiogenesis. Circ Res (2007) 4.67
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer (2005) 3.93
Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res (2003) 3.04
Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol (2004) 2.68
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler (2010) 2.45
Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med (2004) 2.42
Translational control of the innate immune response through IRF-7. Nature (2008) 2.30
Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther (2004) 2.17
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol (2006) 2.16
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 2.15
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 2.14
Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell (2011) 1.95
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Suppression of PKR promotes network excitability and enhanced cognition by interferon-γ-mediated disinhibition. Cell (2011) 1.89
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 1.60
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res (2013) 1.55
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res (2009) 1.53
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
EGFR expression variance in paired colorectal cancer primary and metastatic tumors. Cancer Biol Ther (2010) 1.44
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A (2010) 1.39
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther (2011) 1.39
Cigarette smoke impacts immune inflammatory responses to influenza in mice. Am J Respir Crit Care Med (2006) 1.38
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther (2010) 1.38
Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res (2006) 1.36
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst (2006) 1.36
Visual discrimination learning in zebrafish (Danio rerio). Behav Processes (2005) 1.35
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther (2004) 1.35
Targeting tumor vasculature with an oncolytic virus. Mol Ther (2011) 1.35
Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol (2005) 1.34
Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha-actinin-4. J Am Soc Nephrol (2003) 1.33
Housekeeping genes; expression levels may change with density of cultured cells. J Immunol Methods (2010) 1.32
Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res (2006) 1.31
Oocyte-granulosa cell interactions during mouse follicular development: regulation of kit ligand expression and its role in oocyte growth. Reprod Biol Endocrinol (2006) 1.27
The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol (2008) 1.26
Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol (2007) 1.26
Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther (2007) 1.22
Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev (2008) 1.22
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther (2010) 1.22
Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene (2004) 1.19
Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell (2007) 1.18
Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol (2008) 1.16
Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR. J Virol (2004) 1.15
Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One (2009) 1.14
Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. J Virol (2005) 1.14
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med (2013) 1.13